Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi licenses Neurocrine movement disorders drug

This article was originally published in Scrip

Executive Summary

Mitsubishi Tanabe has licensed the development and commercialization rights in Japan and other Asian markets for Neurocrine Biosciences' VMAT2 inhibitor, NBI-98854. Initially, Mitsubishi Tanabe will develop NBI-98854 in Japan for the chorea associated with Huntington's disease and tardive dyskinesia. Neurocrine will receive an initial payment of $30m and is eligible to receive up to $85m in additional milestone payments associated with the development and commercialization of NBI-98854 in Asia. It will also receive royalties on product sales in the relevant markets. The vesicular monoamine transporter 2 inhibitor product is already in Phase III tardive dyskinesia. It is designed to regulate levels of dopamine release during nerve communication but with fewer off-target side-effects. In addition to Japan, Mitsubishi Tanabe's territory also includes China, South Korea, Philippines, Indonesia, Taiwan, Singapore, Malaysia, Thailand, and Hong Kong. Neurocrine retains full commercial rights to NBI-98854 in North America, Europe and other countries outside of Asia.

You may also be interested in...



QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.

Topics

Related Companies

UsernamePublicRestriction

Register

SC028302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel